News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
489,036 Results
Type
Article (8023)
Company Profile (144)
Press Release (480869)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166755)
Career Advice (304)
Deals (25744)
Drug Delivery (7)
Drug Development (52877)
Employer Resources (14)
FDA (9761)
Job Trends (8572)
News (238212)
Policy (17899)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (2)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (501)
Accelerated approval (31)
ADA (18)
Adcomms (1)
Allergies (102)
Alliances (33158)
ALS (122)
Alzheimer's disease (1006)
Antibody-drug conjugate (ADC) (332)
Approvals (10489)
Artificial intelligence (377)
ASCO (160)
Autoimmune disease (244)
Automation (34)
Bankruptcy (264)
Belgium (4)
Best Places to Work (6958)
BIO (36)
Biologics (54)
BIOSECURE Act (1)
Biosimilars (125)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (28)
Bladder cancer (146)
Brain cancer (36)
Breast cancer (549)
Cancer (4093)
Cardiovascular disease (244)
Career advice (245)
Career pathing (1)
CAR-T (191)
CDC (2)
CDMO (33)
Celiac Disease (3)
Cell therapy (525)
Cervical cancer (37)
Clinical research (48548)
Collaboration (1372)
Commercialization (30)
Compensation (1648)
Complete response letters (36)
COVID-19 (773)
CRISPR (71)
C-suite (867)
Cystic fibrosis (89)
Data (6531)
Denatured (4)
Depression (109)
Dermatology (101)
Diabetes (384)
Diagnostics (4277)
Digital health (43)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (173)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (175)
Earnings (74282)
Editorial (1)
Employer branding (2)
Employer resources (14)
ESMO (238)
Events (89087)
Executive appointments (741)
Eye disease (6)
FDA (12713)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (20)
Frontotemporal dementia (25)
Funding (1005)
Gene editing (136)
Generative AI (15)
Gene therapy (357)
GLP-1 (314)
Government (953)
Grass and pollen (2)
Guidances (286)
Healthcare (9425)
Hematology (115)
HIV (58)
Huntington's disease (29)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (82)
Immunology and inflammation (114)
Immuno-oncology (75)
Indications (187)
Infectious disease (981)
Inflammatory bowel disease (144)
Inflation Reduction Act (4)
Influenza (90)
Intellectual property (273)
Interviews (41)
IPO (12403)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (19)
Kidney disease (90)
Layoffs (59)
Legal (5195)
Licensing (56)
Liver cancer (47)
Longevity (28)
Lung cancer (583)
Lung diease (9)
Lymphoma (279)
Machine learning (30)
Management (3)
Manufacturing (623)
Marketing (24)
MASH (124)
Medical affairs (2)
Medical device (8722)
Medtech (8919)
Mergers & acquisitions (14476)
Metabolic disorders (776)
mRNA (78)
Multiple sclerosis (118)
Multispecific (3)
NASH (4)
Netherlands (3)
Neurodegenerative disease (244)
Neuropsychiatric disorders (40)
Neuroscience (1970)
Neurotech (2)
NextGen: Class of 2026 (3150)
Non-profit (844)
Obesity (242)
Opinion (11)
Ovarian cancer (184)
Pain (194)
Pancreatic cancer (234)
Parkinson's disease (218)
Partnered (12)
Patents (529)
Patient advocacy (3)
Patient recruitment (550)
Patient selection (51)
Peanut (33)
People (41561)
Peptides (20)
Pharmaceutical (30)
Pharmacy benefit managers (11)
Phase 1 (15676)
Phase 2 (21707)
Phase 3 (14645)
Pipeline (8723)
Policy (20)
Postmarket research (1570)
Preclinical (6611)
Press Release (34)
Prostate cancer (210)
Psychedelics (11)
Radiopharmaceuticals (204)
Rare diseases (637)
Real estate (3025)
Recruiting (6)
Regenerative medicine (15)
Regulatory (15230)
Reports (24)
Research institute (595)
Resumes & cover letters (45)
Rett syndrome (47)
RNA editing (9)
RSV (51)
Schizophrenia (111)
Series A (179)
Series B (128)
Service/supplier (5)
Sickle cell disease (69)
Spinal muscular atrophy (93)
Sponsored (5)
Startups (2021)
Stem cells (3)
Stomach cancer (3)
Substance use disorders (17)
Supply chain (56)
Switzerland (2)
Tariffs (2)
Vaccines (358)
Venture capital (18)
Weight loss (78)
Wet AMD (3)
Women's health (101)
Date
Today (162)
Last 7 days (736)
Last 30 days (2098)
Last 365 days (19283)
2026 (16642)
2025 (19253)
2024 (22990)
2023 (26544)
2022 (34589)
2021 (37172)
2020 (33469)
2019 (23263)
2018 (17469)
2017 (18765)
2016 (17918)
2015 (24263)
2014 (21679)
2013 (18136)
2012 (20221)
2011 (20440)
2010 (20334)
Location
Africa (232)
Alabama (80)
Alaska (2)
Arizona (325)
Arkansas (12)
Asia (18092)
Australia (2126)
California (13185)
Canada (3416)
China (591)
Colorado (540)
Connecticut (458)
Delaware (231)
Europe (24848)
Florida (1972)
Georgia (417)
Hawaii (3)
Idaho (46)
Illinois (795)
India (65)
Indiana (337)
Iowa (19)
Japan (464)
Kansas (104)
Kentucky (34)
Louisiana (30)
Maine (27)
Maryland (1298)
Massachusetts (8636)
Michigan (324)
Minnesota (614)
Mississippi (5)
Missouri (84)
Montana (20)
Nebraska (11)
Nevada (136)
New Hampshire (61)
New Jersey (2900)
New Mexico (12)
New York (3087)
North Carolina (1405)
North Dakota (4)
Northern California (6685)
Ohio (308)
Oklahoma (15)
Oregon (17)
Pennsylvania (2460)
Puerto Rico (24)
Rhode Island (32)
South America (407)
South Carolina (81)
South Dakota (1)
Southern California (5512)
Tennessee (129)
Texas (2175)
United States (42701)
Utah (404)
Vermont (1)
Virginia (169)
Washington D.C. (39)
Washington State (1009)
West Virginia (1)
Wisconsin (82)
Wyoming (1)
489,036 Results for "ribomic inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
May 7, 2025
·
3 min read
Press Releases
RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older
October 7, 2025
·
5 min read
Drug Development
RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)
RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that the Eye has published full results from the phase 1 (SUSHI) and phase 2 (TOFU/RAMEN/TEMPURA) trials evaluating the efficacy and safety of intravitreal umedaptanib pegol in nAMD1,2.
December 5, 2023
·
5 min read
RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration
RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the results from the investigator sponsored trial (IST), TEMPURA, along with updated data from its TOFU and RAMEN studies with RBM-007, an investigational anti-fibroblast growth factor-2 aptamer, in wet age-related macular degeneration (wAMD).
March 23, 2022
·
5 min read
Drug Development
RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia
RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), announced the results from its Phase 1, healthy volunteer clinical study using RBM-007 for the planned treatment of Achondroplasia, which was completed in May this year.
November 15, 2021
·
4 min read
Drug Development
RIBOMIC Announces Preliminary Topline Data From Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration
RIBOMIC, Inc. today announced the topline data from the Phase 2 TOFU study of RBM-007 in patients with Wet Age-Related Macular Degeneration (wAMD).
December 28, 2021
·
3 min read
Press Releases
RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort
November 5, 2024
·
5 min read
Press Releases
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
October 1, 2026
·
2 min read
Drug Development
RIBOMIC Announces Completion of IND Submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia
RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that it submitted an Investigational New Drug Application (IND) for an observational study to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
April 19, 2022
·
3 min read
Business
RIBOMIC Enters License Agreement with AJU Pharma for RBM-007 in Age-related Macular Degeneration
RIBOMIC Inc. , today announced that RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Sout
March 17, 2020
·
5 min read
1 of 48,904
Next